Clinical Research
Atherosclerosis
Race and Gender Differences in C-Reactive Protein Levels

https://doi.org/10.1016/j.jacc.2005.04.051Get rights and content
Under an Elsevier user license
open archive

Objectives

This study sought to determine whether there are race and gender differences in the distribution of C-reactive protein (CRP) levels.

Background

Few data are available comparing CRP distributions in different race and gender groups. Recent clinical practice recommendations for CRP testing for cardiovascular risk assessment suggest a uniform threshold to define high relative risk (>3 mg/l).

Methods

We measured CRP in 2,749 white and black subjects ages 30 to 65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample, and compared levels of CRP between different race and gender groups.

Results

Black subjects had higher CRP levels than white subjects (median, 3.0 vs. 2.3 mg/l; p < 0.001) and women had higher CRP levels than men (median, 3.3 vs. 1.8 mg/l; p < 0.001). The sample-weight adjusted proportion of subjects with CRP levels >3 mg/l was 31%, 40%, 51%, and 58% in white men, black men, white women, and black women, respectively (p < 0.05 for each group vs. white men). After adjustment for traditional cardiovascular risk factors, estrogen and statin use, and body mass index, a CRP level >3 mg/l remained more common in white women (odds ratio [OR] 1.6; 95% confidence interval [CI] 1.1 to 2.5) and black women (OR 1.7; 95% CI 1.2 to 2.6) but not in black men (OR, 1.3; 95% CI, 0.8 to 1.9) when compared with white men.

Conclusions

Significant race and gender differences exist in the population distribution of CRP. Further research is needed to determine whether race and gender differences in CRP levels contribute to differences in cardiovascular outcomes, and whether thresholds for cardiovascular risk assessment should be adjusted for different race and gender groups.

Abbreviations and Acronyms

AHA
American Heart Association
BMI
body mass index
CDC
Centers for Disease Control and Prevention
CRP
C-reactive protein
CV
cardiovascular

Cited by (0)

The Dallas Heart Study was funded by the Donald W. Reynolds Foundation (Las Vegas, Nevada). These studies were partially supported by USPHS GCRC grant #M01-RR00633 from NIH/NCRR-CR. The C-reactive protein measurement was supported by Roche Diagnostics (Indianapolis, Indiana). Dr. de Lemos received research grant support from Roche Diagnostics.